A new approach to cancer treatment, utilizing messenger RNA (mRNA) technology to circumvent the ways tumors evade the body’s immune defenses, is showing promise. Researchers in South Korea have developed an mRNA cancer vaccine designed to target both immune cells and cancer cells simultaneously, building on the success of mRNA vaccines used during the COVID-19 pandemic. This innovative strategy aims to overcome a key challenge in cancer immunotherapy: the ability of tumors to “hide” from the immune system.
Sungkyunkwan University announced on March 24th that a research team led by Professors Kwon Dae-hyuk and Yang Yu-soo of the Department of Convergent Bioengineering, in collaboration with the bio-company MVRIX, has developed this dual-targeting mRNA cancer vaccine platform. The findings were published in the international academic journal ACS Nano on March 17th. DOI: 10.1021/acsnano.5c20535
mRNA cancer vaccines work by delivering mRNA containing information about cancer cells into the body, effectively training the immune system to recognize and attack the tumor. Traditional mRNA vaccines focused on delivering this information to dendritic cells – the immune system’s “command centers” – which then initiate an immune response. However, cancer cells can employ a tactic called “antigen escape,” where they stop displaying the markers that the vaccine targets, rendering the immune system unable to recognize them. This significantly reduces the vaccine’s effectiveness.
Targeting Both Immune Cells and Cancer Cells
The research team focused on a protein called DEC-205, which is abundant on both dendritic cells and certain cancer cells, including those found in pancreatic and bladder cancers. Recognizing that DEC-205 acts as a common marker, the researchers engineered the vaccine to deliver mRNA to both cell types simultaneously. This dual-targeting approach is the core innovation of the new platform.
When the mRNA reaches dendritic cells, it instructs them to launch an immune attack against the cancer cells. Simultaneously, the mRNA delivered to the cancer cells forces them to produce and display the target protein on their surface, even if they were previously attempting to hide it. This prevents antigen escape and ensures the immune system has a consistent target. “This effectively addresses the limitations of previous vaccines, which were vulnerable to the cancer’s ability to evade immune detection,” explains Dr. Grace Chen, a board-certified physician and medical writer.
Enhanced Delivery with Lipid Nanoparticles
To ensure efficient delivery of the mRNA, the team utilized lipid nanoparticles (LNPs) – tiny, fat-based capsules that carry the mRNA to the cells. They enhanced these LNPs by attaching antibodies that specifically recognize DEC-205. This “guided missile” approach leverages the properties of cholesterol transport proteins in the blood, allowing the antibodies to attach to the capsule surface without complex chemical processing. The resulting LNPs demonstrated significantly improved mRNA delivery to tumor tissues compared to conventional methods.
Promising Results in Animal Studies
Animal studies demonstrated both the anti-cancer efficacy and relapse prevention capabilities of the dual-targeting vaccine. In mice with colon cancer, two doses of the vaccine led to a substantial increase in T cells – immune cells that directly attack cancer cells – resulting in strong tumor suppression. Similarly, mice with breast cancer exhibited significantly prolonged survival rates, and no toxic side effects were observed.
Perhaps most encouragingly, when tumors were removed and cancer cells were reintroduced, the vaccinated group showed no signs of recurrence. This indicates the development of “immunological memory,” where the immune system remembers the cancer cells and is prepared to eliminate them if they reappear. This is a critical step towards long-term cancer control.
A Personalized Approach to Cancer Immunotherapy
“We have successfully integrated two strategies into a single platform: educating immune cells about the target and preventing cancer cells from hiding it,” said Professor Yang Yu-soo. “This represents a significant advancement towards the development of next-generation, personalized cancer immunotherapies.”
The development of this dual-targeting mRNA vaccine represents a significant step forward in cancer immunotherapy. While still in the early stages of research, the promising results in animal models suggest a potential new avenue for treating cancers that have historically been difficult to target. Further research and clinical trials will be necessary to determine the vaccine’s safety and efficacy in humans. The team is now focused on tailoring this platform to individual patient characteristics, paving the way for truly personalized cancer treatments.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next step for the research team is to initiate pre-clinical studies to refine the vaccine formulation and assess its safety profile in preparation for potential human clinical trials. We will continue to follow this research and provide updates as they become available. Share your thoughts on this promising development in the comments below.
